LB Pharmaceuticals (LBRX) vs Ocular Therapeutix (OCUL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
LB Pharmaceuticals (LBRX) has outperformed Ocular Therapeutix (OCUL) over the past year, gaining 153.4% versus a loss of 54.5%. LB Pharmaceuticals is the larger company by market cap ($1.26 billion vs $1.23 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LBRX | OCUL |
|---|---|---|
| Share price | $38.85 | $5.57 |
| Market cap | $1.26B | $1.23B |
| 1-day change | -2.97% | -4.95% |
| YTD return | +74.53% | -54.12% |
| 1-year return | +153.42% | -54.49% |
| 5-year return | — | -14.83% |
| EPS (TTM) | $-1.12 | $-1.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $51.95M |
| Revenue growth (YoY) | — | -18.47% |
| Net income (latest FY) | $-25.20M | $-265.94M |
| Gross margin | — | 87.35% |
| Operating margin | — | -519.75% |
| Net margin | — | -511.90% |
| 52-week high | $50.16 | $16.44 |
| 52-week low | $15.55 | $5.54 |
| Distance from 52-week high | -22.55% | -66.12% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +49.29% | +361.94% |
| Average volume | 373.16K | 3.03M |
| Shares outstanding | 32.36M | 220.02M |
| Employees | 62 | 325 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LBRX has outperformed OCUL by 207.9 percentage points over the past year.
About LB Pharmaceuticals
LBRX stock →LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation.
Health Care · Biotechnology: Pharmaceutical Preparations · 62 employees
About Ocular Therapeutix
OCUL stock →Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 325 employees
LBRX vs OCUL FAQ
Which is bigger, LB Pharmaceuticals or Ocular Therapeutix?
LB Pharmaceuticals (LBRX) is larger, with a market capitalization of $1.26B compared with $1.23B for Ocular Therapeutix (OCUL).
Which stock has performed better over the past year, LBRX or OCUL?
LBRX returned +153.42% over the past 12 months, compared with -54.49% for OCUL (price return, excluding dividends). Past performance does not predict future results.
Are LB Pharmaceuticals and Ocular Therapeutix in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.